PURPOSE:
This study by Hanley et al. (Obstetrics & Gynecology, 2017) aimed to analyze the relationship between interpregnancy interval and adverse pregnancy outcomes.
METHODS:
Retrospective Cohort Study, using successive pregnancies to serve as matched controls
RESULTS:
38,178 women with three or more deliveries were surveyed. Pregnancy interval was compared to neonatal outcomes including preterm birth (< 37 weeks’ gestation), small for gestational age (< 10th centile), need for neonatal intensive care and low birth weight (<2,500 g). Maternal outcomes were also assessed and included gestational diabetes, preeclampsia / eclampsia, and obesity (BMI ≥ 30). When women served as their own controls based upon successive pregnancies, many adverse outcomes disappeared, suggesting that study design may explain the different findings in some previous studies. Short interpregnancy (0 to 5 months) interval was still associated with higher risk of beginning subsequent pregnancies with elevated BMIs in the obese range as well as GDM.
Learn More – Primary Sources:
Interpregnancy Interval and Adverse Pregnancy Outcomes: An Analysis of Successive Pregnancies
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
